A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

• Published in: The American journal of psychiatry Vol. 163; no. 12; pp. 2072 - 2079
• Main Authors: Klein, David J., Cottingham, Elizabeth M., Sorter, Michael, Barton, Bruce A., Morrison, John A.
• Format: Journal Article
• Language: English
• Published: Washington, DC American Psychiatric Association 01.12.2006
• Subjects: Adolescent; Age Factors; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Biological and medical sciences; Blood Glucose - analysis; Body Mass Index; Changes; Child; Children & youth; Clinical outcomes; Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - prevention & control; Double-Blind Method; Drug therapy; Glucose Tolerance Test; Humans; Hypoglycemic Agents - therapeutic use; Insulin - blood; Insulin Resistance; Intellectual disabilities; Medical sciences; Mental Disorders - drug therapy; Mental Disorders - metabolism; Metformin - therapeutic use; Obesity - chemically induced; Obesity - drug therapy; Patients; Placebos; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychotropic drugs; Risk factors; Side effects; Studies; Weight; Weight Gain - drug effects; Human; Atypical antipsychotic; Psychotropic; Weight gain; Chemotherapy; Hypoglycemic agent; Biguanides; Treatment; Adolescent; Placebo; Double blind study; Metformin; Child

Objective: Second-generation, or atypical, antipsychotics effectively treat psychiatric illness in children and adolescents. However, weight gain and abnormalities in insulin sensitivity, including diabetes, complicate this therapy. Method: A 16-week double-blind, placebo-controlled trial was conduc...